Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
Abstract Purpose We aimed to evaluate adherence to oral antineoplastic therapy (OAT) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and its potential relationship with several clinical outcomes. Methods Observational, prospective, multicenter study performed by 6...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-08-01
|
| Series: | Journal of Cancer Research and Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00432-025-06264-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849334046287462400 |
|---|---|
| author | Irene Mangues-Bafalluy Beatriz Bernardez José Manuel Martínez-Sesmero Andres Navarro-Ruiz Maria Teresa Martín-Conde Ana Rosa Rubio-Salvador Judith Rius-Perera Marta Gilabert-Sotoca Marta Domínguez López Angel Callejo Mellén |
| author_facet | Irene Mangues-Bafalluy Beatriz Bernardez José Manuel Martínez-Sesmero Andres Navarro-Ruiz Maria Teresa Martín-Conde Ana Rosa Rubio-Salvador Judith Rius-Perera Marta Gilabert-Sotoca Marta Domínguez López Angel Callejo Mellén |
| author_sort | Irene Mangues-Bafalluy |
| collection | DOAJ |
| description | Abstract Purpose We aimed to evaluate adherence to oral antineoplastic therapy (OAT) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and its potential relationship with several clinical outcomes. Methods Observational, prospective, multicenter study performed by 6 hospital pharmacists in Spain. The primary outcome was the proportion of treatment adherence as evaluated by pill reconciliation during the 3-month active follow-up period. Those with an adherence > 80% were categorized as adherent. We performed multivariate Cox regression analyses to explore the factors associated with progression-free survival. Results From December 2019 to November 2022, we recruited 95 evaluable patients. Most of the patients received osimertinib (n = 45, 45.3%) or a first- or second-generation tyrosine kinase inhibitor (n = 23, 34.8%). Eighty-one patients showed greater than 80% adherence (85.3%, 95% CI 78.1% to 92.4%), as evaluated based on pill reconciliation; the mean (SD) adherence to OAT was 94.7% (11.4). According to the univariate analysis, the time to progression from study entry was significantly shorter among patients who were nonadherent than among those who were adherent (median 6.5 months vs. not reached, log-rank test p = 0.006; hazard ratio [HR] 2.619, 95% confidence interval [CI] 1.240–5.532). In the multivariate Cox regression analysis, nonadherence was the single factor associated with progression-free survival. Conclusion Consistent with previous evidence in this setting, our results suggest that adherence to oral antineoplastic treatment among patients with NSCLC is high. Whether this high rate of adherence translates to better clinical outcomes should be further evaluated in larger samples. |
| format | Article |
| id | doaj-art-dc7f36cfd2b94fb5a915eb22df01280a |
| institution | Kabale University |
| issn | 1432-1335 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Springer |
| record_format | Article |
| series | Journal of Cancer Research and Clinical Oncology |
| spelling | doaj-art-dc7f36cfd2b94fb5a915eb22df01280a2025-08-20T03:45:40ZengSpringerJournal of Cancer Research and Clinical Oncology1432-13352025-08-0115181910.1007/s00432-025-06264-0Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective studyIrene Mangues-Bafalluy0Beatriz Bernardez1José Manuel Martínez-Sesmero2Andres Navarro-Ruiz3Maria Teresa Martín-Conde4Ana Rosa Rubio-Salvador5Judith Rius-Perera6Marta Gilabert-Sotoca7Marta Domínguez López8Angel Callejo Mellén9Servicio de Farmacia, Hospital Universitari Arnau de Vilanova LleidaServicio de Farmacia, Complejo Hospitalario Universitario de Santiago de CompostelaServicio de Farmacia, Hospital Clínico Universitario Lozano BlesaServicio de Farmacia, Hospital General Universitario de ElcheServicio de Farmacia, Hospital Clínic de BarcelonaServicio de Farmacia, Complejo Hospitalario de ToledoServicio de Farmacia, Hospital Universitari Arnau de Vilanova LleidaServicio de Farmacia, Hospital Universitari Arnau de Vilanova LleidaAstraZeneca Farmacéutica SpainAstraZeneca Farmacéutica SpainAbstract Purpose We aimed to evaluate adherence to oral antineoplastic therapy (OAT) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and its potential relationship with several clinical outcomes. Methods Observational, prospective, multicenter study performed by 6 hospital pharmacists in Spain. The primary outcome was the proportion of treatment adherence as evaluated by pill reconciliation during the 3-month active follow-up period. Those with an adherence > 80% were categorized as adherent. We performed multivariate Cox regression analyses to explore the factors associated with progression-free survival. Results From December 2019 to November 2022, we recruited 95 evaluable patients. Most of the patients received osimertinib (n = 45, 45.3%) or a first- or second-generation tyrosine kinase inhibitor (n = 23, 34.8%). Eighty-one patients showed greater than 80% adherence (85.3%, 95% CI 78.1% to 92.4%), as evaluated based on pill reconciliation; the mean (SD) adherence to OAT was 94.7% (11.4). According to the univariate analysis, the time to progression from study entry was significantly shorter among patients who were nonadherent than among those who were adherent (median 6.5 months vs. not reached, log-rank test p = 0.006; hazard ratio [HR] 2.619, 95% confidence interval [CI] 1.240–5.532). In the multivariate Cox regression analysis, nonadherence was the single factor associated with progression-free survival. Conclusion Consistent with previous evidence in this setting, our results suggest that adherence to oral antineoplastic treatment among patients with NSCLC is high. Whether this high rate of adherence translates to better clinical outcomes should be further evaluated in larger samples.https://doi.org/10.1007/s00432-025-06264-0Non-small cell lung cancerOral chemotherapyTyrosine kinase inhibitorsAnaplastic lymphoma kinase inhibitorsAdherenceProgression-free survival |
| spellingShingle | Irene Mangues-Bafalluy Beatriz Bernardez José Manuel Martínez-Sesmero Andres Navarro-Ruiz Maria Teresa Martín-Conde Ana Rosa Rubio-Salvador Judith Rius-Perera Marta Gilabert-Sotoca Marta Domínguez López Angel Callejo Mellén Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study Journal of Cancer Research and Clinical Oncology Non-small cell lung cancer Oral chemotherapy Tyrosine kinase inhibitors Anaplastic lymphoma kinase inhibitors Adherence Progression-free survival |
| title | Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study |
| title_full | Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study |
| title_fullStr | Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study |
| title_full_unstemmed | Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study |
| title_short | Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study |
| title_sort | adherence to oral antineoplastic therapy among patients with advanced or metastatic non small cell lung cancer a noninterventional prospective study |
| topic | Non-small cell lung cancer Oral chemotherapy Tyrosine kinase inhibitors Anaplastic lymphoma kinase inhibitors Adherence Progression-free survival |
| url | https://doi.org/10.1007/s00432-025-06264-0 |
| work_keys_str_mv | AT irenemanguesbafalluy adherencetooralantineoplastictherapyamongpatientswithadvancedormetastaticnonsmallcelllungcanceranoninterventionalprospectivestudy AT beatrizbernardez adherencetooralantineoplastictherapyamongpatientswithadvancedormetastaticnonsmallcelllungcanceranoninterventionalprospectivestudy AT josemanuelmartinezsesmero adherencetooralantineoplastictherapyamongpatientswithadvancedormetastaticnonsmallcelllungcanceranoninterventionalprospectivestudy AT andresnavarroruiz adherencetooralantineoplastictherapyamongpatientswithadvancedormetastaticnonsmallcelllungcanceranoninterventionalprospectivestudy AT mariateresamartinconde adherencetooralantineoplastictherapyamongpatientswithadvancedormetastaticnonsmallcelllungcanceranoninterventionalprospectivestudy AT anarosarubiosalvador adherencetooralantineoplastictherapyamongpatientswithadvancedormetastaticnonsmallcelllungcanceranoninterventionalprospectivestudy AT judithriusperera adherencetooralantineoplastictherapyamongpatientswithadvancedormetastaticnonsmallcelllungcanceranoninterventionalprospectivestudy AT martagilabertsotoca adherencetooralantineoplastictherapyamongpatientswithadvancedormetastaticnonsmallcelllungcanceranoninterventionalprospectivestudy AT martadominguezlopez adherencetooralantineoplastictherapyamongpatientswithadvancedormetastaticnonsmallcelllungcanceranoninterventionalprospectivestudy AT angelcallejomellen adherencetooralantineoplastictherapyamongpatientswithadvancedormetastaticnonsmallcelllungcanceranoninterventionalprospectivestudy |